GLP-2 Delays but does not prevent the onset of necrotizing enterocolitis in preterm pigs

Journal of Pediatric Gastroenterology and Nutrition

Volumn 56, Issue 6, 2013, Pages 623-630

  Benight, Nancy M ^a   Stoll, Barbara ^a   Olutoye, Oluyinka O ^b   Holst, Jens J ^c   Burrin, Douglas G ^a  

^a CHILDREN S NUTRITION RESEARCH CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

inflammation; neonate; serum amyloid A

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; KI 67 ANTIGEN; MYELOPEROXIDASE; SERUM AMYLOID A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ARTIFICIAL MILK; CONTINUOUS INFUSION; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DISEASE SEVERITY; DRUG WITHDRAWAL; ENTERIC FEEDING; ENZYME ACTIVITY; HISTOPATHOLOGY; INJURY SEVERITY; INTESTINAL WEIGHT; INTESTINE CRYPT; INTESTINE VILLUS; NECROTIZING ENTEROCOLITIS; NONHUMAN; ORGAN WEIGHT; OVERALL SURVIVAL; PIGLET; PREMATURITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SURVIVAL TIME; TOTAL PARENTERAL NUTRITION; VILLUS HEIGHT;

ANIMALS; ANIMALS, INBRED STRAINS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CESAREAN SECTION; DISEASE MODELS, ANIMAL; ENTEROCOLITIS, NECROTIZING; FEMALE; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INFUSIONS, PARENTERAL; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICROVILLI; PARENTERAL NUTRITION, TOTAL; PREGNANCY; PREMATURE BIRTH; RANDOM ALLOCATION; SERUM AMYLOID A PROTEIN; TEXAS; UP-REGULATION;

SUIDAE;

EID: 84878933407     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e318286891e     Document Type: Article

References (44)

1. Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet 2006;368:1271-83.
2. Lin PW, Nasr TR, Stoll BJ. Necrotizing enterocolitis: recent scientific advances in pathophysiology and prevention. Semin Perinatol 2008; 32:70-82.
3. Christensen RD, Henry E, Wiedmeier SE, et al. Identifying patients, on the first day of life, at high-risk of developing parenteral nutritionassociated liver disease. J Perinatol 2007;27:284-90.
4. Christensen RD, Henry E, Kiehn TI, et al. Pattern of daily weights among low birth weight neonates in the neonatal intensive care unit: data from a multihospital health-care system. J Perinatol 2006;26:37-43.
5. Thureen PJ, Hay WW Jr. Early aggressive nutrition in preterm infants. Semin Neonatol 2001;6:403-15.
6. Burrin DG, Stoll B, Jiang R, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 2000;279:G1249-56.
7. Stoll B, Chang X, Fan MZ, et al. Enteral nutrient intake level determines intestinal protein synthesis and accretion rates in neonatal pigs. Am J Physiol Gastrointest Liver Physiol 2000;279:G288-94.
8. Shulman RJ. Effect of different total parenteral nutrition fuel mixes on small intestinal growth and differentiation in the infant miniature pig. Gastroenterology 1988;95:85-92.
9. Goldstein RM, Hebiguchi T, Luk GD, et al. The effects of total parenteral nutrition on gastrointestinal growth and development. J Pediatr Surg 1985;20:785-91.
10. Burrin DG, Stoll B, Guan X, et al. Glucagon-like peptide 2 dosedependently activates intestinal cell survival and proliferation in neonatal piglets. Endocrinology 2005;146:22-32.
11. Cottrell JJ, Stoll B, Buddington RK, et al. Glucagon-like peptide-2 protects against TPN-induced intestinal hexose malabsorption in enterally refed piglets. Am J Physiol Gastrointest Liver Physiol 2006;290:G293-300.
12. Benjamin MA, McKay DM, Yang PC, et al. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000;47:112-9.
13. Cani PD, Possemiers S, Van deWiele T, et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58:1091-103.
14. Burrin DG, Petersen Y, Stoll B, et al. Glucagon-like peptide 2: a nutrient-responsive gut growth factor. J Nutr 2001;131:709-12.
15. Drucker DJ. Glucagon-like peptide 2. Trends Endocrinol Metab 1999; 10:153-6.
16. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr 2006;26:391-411.
17. Xiao Q, Boushey RP, Cino M, et al. Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease. Am J Physiol Regul Integr Comp Physiol 2000;278:R1057-63.
18. Alavi K, Schwartz MZ, Palazzo JP, et al. Treatment of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000;35:847-51.
19. Yazbeck R, Sulda ML, Howarth GS, et al. Dipeptidyl peptidase expression during experimental colitis in mice. Inflamm Bowel Dis 2010;16:1340-51.
20. Sigalet DL, Wallace L, De Heuval E, et al. The effects of glucagonlike peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil 2010;22:1318-50.
21. Flock G, Holland D, Seino Y, et al. GPR119 regulates murine glucose homeostasis through incretin receptor-dependent and independent mechanisms. Endocrinology 2011;152:374-83.
22. Jeppesen PB, Hartmann B, Thulesen J, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001;120:806-15.
23. Jeppesen PB, Sanguinetti EL, Buchman A, et al. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut 2005;54:1224-31.
24. Jeppesen PB, Lund P, Gottschalck IB, et al. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009;2009:616054.
25. Jeppesen PB, Gilroy R, Pertkiewicz M, et al. Randomised placebocontrolled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome. Gut 2011;60:902-14.
26. Kitchen PA, Goodlad RA, FitzGerald AJ, et al. Intestinal growth in parenterally-fed rats induced by the combined effects of glucagon-like peptide 2 and epidermal growth factor. JPEN J Parenter Enteral Nutr 2005;29:248-54.
27. Mouksassi MS, Marier JF, Cyran J, et al. Clinical trial simulations in pediatric patients using realistic covariates: application to teduglutide, a glucagon-like peptide-2 analog in neonates and infants with short-bowel syndrome. Clin Pharmacol Ther 2009;86:667-71.
28. Okawada M, Holst JJ, Teitelbaum DH. Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome. Surgery 2011;150:217-23.
29. Sigalet DL, Bawazir O, Martin GR, et al. Glucagon-like peptide-2 induces a specific pattern of adaptation in remnant jejunum. Dig Dis Sci 2006;51:1557-66.
30. Sangild PT, Petersen YM, Schmidt M, et al. Preterm birth affects the intestinal response to parenteral and enteral nutrition in newborn pigs. J Nutr 2002;132:3786-94.
31. Sangild PT, Siggers RH, Schmidt M, et al. Diet- and colonizationdependent intestinal dysfunction predisposes to necrotizing enterocolitis in preterm pigs. Gastroenterology 2006;130:1776-92.
32. Bauchart-Thevret C, Stoll B, Chacko S, et al. Sulfur amino acid deficiency upregulates intestinal methionine cycle activity and suppresses epithelial growth in neonatal pigs. Am J Physiol Endocrinol Metab 2009;296:E1239-50.
33. Yu X, Radulescu A, Zorko N, et al. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology 2009;137:221-30.
34. Caplan MS, Hedlund E, Adler L, et al. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatr Pathol 1994;14:1017-28.
35. Burrin DG, Stoll B, Jiang R, et al. Minimal enteral nutrient requirements for intestinal growth in neonatal piglets: how much is enough? Am J Clin Nutr 2000;71:1603-10.
36. Fahrenkrug J, Schaffalitzky de Muckadell OV. Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma. J Lab Clin Med 1977;89:1379-88.
37. SuzukiK, Ota H, Sasagawa S, et al. Assay method for myeloperoxidase in human polymorphonuclear leukocytes. Anal Biochem 1983;132:345-52.
38. Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 1984;87:1344-50.
39. Tayman C, Tonbul A, Kosus A, et al. Protective effects of caffeic acid phenethyl ester (CAPE) on intestinal damage in necrotizing enterocolitis. Pediatr Surg Int 2011;27:1179-89.
40. Musemeche CA, Baker JL, Feddersen RM. A model of intestinal ischemia in the neonatal rat utilizing superior mesenteric artery occlusion and intraluminal platelet-activating factor. J Surg Res 1995; 58:724-7.
41. Ng PC, Ang IL, Chiu RW, et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest 2010;120:2989-3000.
42. Maury CP. Comparative study of serum amyloid A protein and C-reactive protein in disease. Clin Sci (Lond) 1985;68:233-8.
43. Taylor-Edwards CC, Burrin DG, Holst JJ, et al. Glucagon-like peptide-2 (GLP-2) increases small intestinal blood flow and mucosal growth in ruminating calves. J Dairy Sci 2011;94: 888-98.
44. Petersen YM, Burrin DG, Sangild PT. GLP-2 has differential effects on small intestine growth and function in fetal and neonatal pigs. Am J Physiol Regul Integr Comp Physiol 2001;281:R1986-93.